Screener
Acadia Pharmaceuticals ACAD Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net income | $35,137 | $45,653 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Stock-based compensation | 31,638 | 25,720 |
| Amortization of premiums and accretion of discounts on investment securities | (503) | (3,652) |
| Amortization of intangible assets | 5,445 | 5,444 |
| Depreciation | 705 | 442 |
| Deferred Income Taxes | 9,679 | — |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's stock-based comp?
- Acadia Pharmaceuticals (ACAD) reported stock-based comp of $16.94M in Q2 2026.
- How has Acadia Pharmaceuticals's stock-based comp changed year-over-year?
- Acadia Pharmaceuticals's stock-based comp increased by 18.1% year-over-year, from $14.34M to $16.94M.
- What is the long-term trend for Acadia Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Acadia Pharmaceuticals's stock-based comp has grown at a -4.9% compound annual growth rate (CAGR), from $63.62M to $52.14M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Acadia Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude